Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

UroGen Pharma Ltd.

URGNNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Jun 24, 2026Accepted Jun 24, 2026, 10:00 AM EDTFiling CIK 1668243Accession 0001437749-26-021513
Share

Structured filing — 4

rdgdoc.xml

Open full document ↗

Filing details

Report period
2026-06-22
Issuer
UroGen Pharma Ltd.
Issuer CIK
0001668243
Trading symbol
URGN

Reporting owner 1

Name
BUTITTA CYNTHIA M
Reporting owner CIK
0001222082
Relationship
Director
Address
400 ALEXANDER PARK DRIVE, PRINCETON, NJ, 08540

Derivative transactions

Derivative transactions · 2 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (right ot buy)34.992026-06-22A · Form 410,000A0[F1]2036-06-22Ordinary Shares10,00010,000D
Restricted Stock Unit[F2]2026-06-22A · Form 48,000A0[F3][F3]Ordinary Shares8,0008,000D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.↩ 1
F2
Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer↩ 1
F3
The shares underlying the RSUs will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.↩ 1↩ 2

Signature 1

Signed
/s/ Jason D. Smith, Attorney-in-Fact
Date
2026-06-23

Company context

Current securities

Recent company filings

  1. SCHEDULE 13G/A - filed by TORONTO DOMINION BANK regarding UroGen Pharma Ltd.Nov 13, 2026
  2. S-8 filingNov 4, 2026
  3. 10-Q filingNov 4, 2026
  4. Results of Operations and Financial ConditionNov 4, 2026
  5. 144 filingSep 9, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.